Status and timing of angiotensin receptor–neprilysin inhibitor implementation in patients with heart failure and reduced ejection fraction: Data from the Swedish Heart Failure Registry

Key Points

• Initiation of angiotensin receptor-neprilysin inhibitors in heart failure with reduced ejection fraction shows variation across settings, indicating gaps in treatment.
• Key evidence from the Swedish Heart Failure Registry reveals specific predictors of ARNI initiation, emphasizing patient demographics.
• Exploration of timing and predictors involved observational analysis in a large nationwide cohort of heart failure patients with reduced ejection fraction across diverse clinical settings. Highlights the need to improve timely treatment in this population.